| NCT ID | NCT03032835 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Calciphylaxis |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2017-01 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2017-01 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles. There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis. The Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.
Eligibility Criteria
Inclusion Criteria: 1. Male or female ≥18 years old 2. Skin lesions consistent with calciphylaxis diagnosis as determined by the treating clinician 3. Informed of the investigational nature of the study and sign written Informed consent OR are eligible for surrogate consent process based on impaired decision making Exclusion Criteria: 1. Patients \<18 years of age 2. Prisoners
Contact & Investigator
Sagar U Nigwekar, MD, MMSc
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT03032835 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Calciphylaxis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03032835 currently recruiting?
Yes, NCT03032835 is actively recruiting participants. Contact the research team at snigwekar@mgh.harvard.edu for enrollment information.
Where is the NCT03032835 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT03032835 clinical trial?
NCT03032835 is sponsored by Massachusetts General Hospital. The principal investigator is Sagar U Nigwekar, MD, MMSc at Massachusetts General Hospital. The trial plans to enroll 300 participants.